The multifaceted functions of CXCL10 in cardiovascular disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Van Den Borne, Pleunie ^a   Quax, Paul H A ^b   Hoefer, Imo E ^a,c   Pasterkamp, Gerard ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; BIOLOGICAL MARKER; CHEMOTACTIC FACTOR; CXCL10 PROTEIN, HUMAN;

ANEURYSM; ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CRITICAL LIMB ISCHEMIA; EXPERIMENTAL STUDY; HEART INFARCTION; HUMAN; LEUKOCYTE; LYMPHOCYTE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; VASCULAR SMOOTH MUSCLE; ANIMAL; CHEMISTRY; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANEURYSM; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEMOKINE CXCL10; CHEMOTACTIC FACTORS; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES; LYMPHOCYTES; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; SIGNAL TRANSDUCTION;

EID: 84901294728     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/893106     Document Type: Review

References (86)

1. Schober A., Chemokines in vascular dysfunction and remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 11 1950 1959 2-s2.0-55449118234 10.1161/ATVBAHA.107.161224
2. Bazan J. F., Bacon K. B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D. R., Zlotnik A., Schall T. J., A new class of membrane-bound chemokine with a CX3C motif. Nature 1997 385 6617 640 642 2-s2.0-0031036347 10.1038/385640a0 (Pubitemid 27087578)
3. Romagnani P., Lasagni L., Annunziato F., Serio M., Romagnani S., CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends in Immunology 2004 25 4 201 209 2-s2.0-1642274574 10.1016/j.it.2004.02.006 (Pubitemid 38372168)
4. Zlotnik A., Yoshie O., The chemokine superfamily revisited. Immunity 2012 36 705 716
5. Strieter R. M., Polverini P. J., Arenberg D. A., Walz A., Opdenakker G., van Damme N. J., Lunkel S. L., Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. Journal of Leukocyte Biology 1995 57 5 752 762 2-s2.0-0029067923
6. Strieter R. M., Polverini P. J., Kunkel S. L., Arenberg D. A., Burdick M. D., Kasper J., Dzuiba J., van Damme J., Walz A., Marriott D., Chan S.-Y., Roczniak S., Shanafelt A. B., The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. Journal of Biological Chemistry 1995 270 45 27348 27357 2-s2.0-20244390429 10.1074/jbc.270.45.27348
7. Luster A. D., Ravetch J. V., Biochemical characterization of a γ interferon-inducible cytokine (IP-10). Journal of Experimental Medicine 1987 166 4 1084 1097 2-s2.0-0023604651 (Pubitemid 18024248)
8. Ohmori Y., Hamilton T. A., Cell type and stimulus specific regulation of chemokine gene expression. Biochemical and Biophysical Research Communications 1994 198 2 590 596 2-s2.0-0028243615 10.1006/bbrc.1994.1086 (Pubitemid 24178409)
9. Ohmori Y., Hamilton T. A., The interferon-stimulated response element and a B site mediate synergistic induction of murine IP-10 gene transcription by IFN- γ and TNF- α Journal of Immunology 1995 154 10 5235 5244 2-s2.0-0029034506
10. Loetscher M., Gerber B., Loetscher P., Jones S. A., Piali L., Clark-Lewis I., Baggiolini M., Moser B., Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activate T-Lymphocytes. Journal of Experimental Medicine 1996 184 3 963 969 2-s2.0-0029829106
11. Luster B. A. D., Greenberg S. M., Leder P., The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. Journal of Experimental Medicine 1995 182 1 219 231 2-s2.0-0029060187 10.1084/jem.182.1.219
12. Jiang D., Liang J., Campanella G. S., Guo R., Yu S., Xie T., Liu N., Jung Y., Homer R., Meltzer E. B., Li Y., Tager A. M., Goetinck P. F., Luster A. D., Noble P. W., Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. Journal of Clinical Investigation 2010 120 6 2049 2057 2-s2.0-77953175936 10.1172/JCI38644
13. Campanella G. S. V., Colvin R. A., Luster A. D., CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PloS ONE 2010 5 9 e12700 2-s2.0-79952279528
14. Soejima K., Rollins B. J., A functional IFN- γ -inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. Journal of Immunology 2001 167 11 6576 6582 2-s2.0-0035575935 (Pubitemid 33081594)
15. Wang X., Yue T.-L., Ohlstein E. H., Sung C.-P., Feuerstein G. Z., Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. Journal of Biological Chemistry 1996 271 39 24286 24293 2-s2.0-0029821998 10.1074/jbc.271.39.24286 (Pubitemid 26327418)
16. Taub D. D., Longo D. L., Murphy W. J., Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues of human peripheral blood lymphocytes-SCID mice. Blood 1996 87 4 1423 1431 2-s2.0-0030021788
17. Dufour J. H., Dziejman M., Liu M. T., Leung J. H., Lane T. E., Luster A. D., IFN- γ -inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. Journal of Immunology 2002 168 7 3195 3204 2-s2.0-0036533663 (Pubitemid 34256349)
18. Heller E. A., Liu E., Tager A. M., Yuan Q., Lin A. Y., Ahluwalia N., Jones K., Koehn S. L., Lok V. M., Aikawa E., Moore K. J., Luster A. D., Gerszten R. E., Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006 113 19 2301 2312 2-s2.0-33744981802 10.1161/CIRCULATIONAHA.105.605121 (Pubitemid 43947976)
19. Segers D., Lipton J. A., Leenen P. J. M., Atherosclerotic plaque stability is affected by the chemokine CXCL10 in both mice and humans. International Journal of Inflammation 2011 2011 9 936109 10.4061/2011/936109
20. Cheng C., Tempel D., van Haperen R., De Boer H. C., Segers D., Huisman M., van Zonneveld A. J., Leenen P. J. M., van der Steen A., Serruys P. W., De Crom R., Krams R., Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines. Journal of Clinical Investigation 2007 117 3 616 626 2-s2.0-33847393655 10.1172/JCI28180 (Pubitemid 46348520)
21. Veillard N. R., Steffens S., Pelli G., Lu B., Kwak B. R., Gerard C., Charo I. F., Mach F., Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 2005 112 6 870 878 2-s2.0-23844437323 10.1161/CIRCULATIONAHA.104.520718 (Pubitemid 41170074)
22. van Wanrooij E. J. A., de Jager S. C. A., van Es T., de Vos P., Birch H. L., Owen D. A., Watson R. J., Biessen E. A. L., Chapman G. A., van Berkel T. J. C., Kuiper J., CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 2 251 257 2-s2.0-38549146090 10.1161/ATVBAHA.107.147827 (Pubitemid 351161196)
23. van Wanrooij E. J. A., Happé H., Hauer A. D., De Vos P., Imanishi T., Fujiwara H., van Berkel T. J. C., Kuiper J., HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 12 2642 2647 2-s2.0-33644803365 10.1161/01.ATV.0000192018.90021.c0 (Pubitemid 43732291)
24. King V. L., Lin A. Y., Kristo F., Anderson T. J. T., Ahluwalia N., Hardy G. J., Owens A. P. III, Howatt D. A., Shen D., Tager A. M., Luster A. D., Daugherty A., Gerszten R. E., Interferon- γ and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation 2009 119 3 426 435 2-s2.0-60549090579 10.1161/CIRCULATIONAHA.108.785949
25. MacTaggart J. N., Xiong W., Knispel R., Baxter B. T., Deletion of CCR2 but not CCR5 or CXCR3 inhibits aortic aneurysm formation. Surgery 2007 142 2 284 288 2-s2.0-34547668921 10.1016/j.surg.2007.04.017 (Pubitemid 47208561)
26. Gallo A., Saad A., Ali R., Dardik A., Tellides G., Geirsson A., Circulating interferon- γ -inducible Cys-X-Cys chemokine receptor 3 ligands are elevated in humans with aortic aneurysms and Cys-X-Cys chemokine receptor 3 is necessary for aneurysm formation in mice. Journal of Thoracic and Cardiovascular Surgery 2012 143 3 704 710 2-s2.0-84857233806 10.1016/j.jtcvs.2011.08.036
27. Frangogiannis N. G., Mendoza L. H., Lewallen M., Michael L. H., Smith C. W., Entman M. L., Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. The FASEB Journal 2001 15 8 1428 1430 2-s2.0-0035379769
28. Dewald O., Ren G., Duerr G. D., Zoerlein M., Klemm C., Gersch C., Tincey S., Michael L. H., Entman M. L., Frangogiannis N. G., Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. American Journal of Pathology 2004 164 2 665 677 2-s2.0-1542319857 (Pubitemid 38364680)
29. Bujak M., Dobaczewski M., Gonzalez-Quesada C., Xia Y., Leucker T., Zymek P., Veeranna V., Tager A. M., Luster A. D., Frangogiannis N. G., Induction of the CXC chemokine interferon- γ -inducible protein 10 regulates the reparative response following myocardial infarction. Circulation Research 2009 105 10 973 983 2-s2.0-72449132876 10.1161/CIRCRESAHA.109.199471
30. Lee C. W., Stabile E., Kinnaird T., Shou M., Devaney J. M., Epstein S. E., Burnett M. S., Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. Journal of the American College of Cardiology 2004 43 3 474 482 2-s2.0-0842287504 10.1016/j.jacc.2003.09.033 (Pubitemid 38167711)
31. Waeckel L., Mallat Z., Potteaux S., Combadière C., Clergue M., Duriez M., Bao L., Gerard C., Rollins B. J., Tedgui A., Levy B. I., Silvestre J.-S., Impairment in postischemic neovascularization in mice lacking the CXC chemokine receptor 3. Circulation Research 2005 96 5 576 582 2-s2.0-20144389706 10.1161/01.RES.0000159389.55544.20 (Pubitemid 40463467)
32. van den Borne P., Haverslag R. T., Brandt M., Absence of chemokine (C-X-C Motif) ligand 10 diminishes perfusion recovery after local arterial occlusion in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2014 34 594 602
33. Tang P. C. Y., Yakimov A. O., Teesdale M. A., Coady M. A., Dardik A., Elefteriades J. A., Tellides G., Transmural inflammation by interferon- γ -producing T cells correlates with outward vascular remodeling and intimal expansion of ascending thoracic aortic aneurysms. The FASEB Journal 2005 19 11 1528 1530 2-s2.0-24644523575 10.1096/fj.05-3671fje (Pubitemid 41279020)
34. Abdul-Hussien H., Hanemaaijer R., Kleemann R., Verhaaren B. F. J., van Bockel J. H., Lindeman J. H. N., The pathophysiology of abdominal aortic aneurysm growth: corresponding and discordant inflammatory and proteolytic processes in abdominal aortic and popliteal artery aneurysms. Journal of Vascular Surgery 2010 51 6 1479 1487 2-s2.0-77952210899 10.1016/j.jvs.2010.01. 057
35. Herder C., Baumert J., Thorand B., Martin S., Löwel H., Kolb H., Koenig W., Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 9 2147 2152 2-s2.0-33747399412 10.1161/01.ATV.0000235691.84430.86 (Pubitemid 44253801)
36. Rothenbacher D., Müller-Scholze S., Herder C., Koenig W., Kolb H., Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 1 194 199 2-s2.0-33644823999 10.1161/01.ATV.0000191633.52585.14 (Pubitemid 43732249)
37. Ardigo D., Assimes T. L., Fortmann S. P., Go A. S., Hlatky M., Hytopoulos E., Iribarren C., Tsao P. S., Tabibiazar R., Quertermous T., Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiological Genomics 2007 31 3 402 409 2-s2.0-36248950222 10.1152/physiolgenomics.00104.2007 (Pubitemid 350127780)
38. Oliveira R. T. D. D., Mamoni R. L., Souza J. R. M., Fernandes J. L., Rios F. J. O., Gidlund M., Coelho O. R., Blotta M. H. S. L., Differential expression of cytokines, chemokines and chemokine receptors in patients with coronary artery disease. International Journal of Cardiology 2009 136 1 17 26 2-s2.0-67649842771 10.1016/j.ijcard.2008.04.009
39. Keeley E. C., Moorman J. R., Liu L., Gimple L. W., Lipson L. C., Ragosta M., Taylor A. M., Lake D. E., Burdick M. D., Mehrad B., Strieter R. M., Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS ONE 2011 6 6 2-s2.0-79959395141 10.1371/journal.pone.0021174 e21174
40. Koten K., Hirohata S., Miyoshi T., Ogawa H., Usui S., Shinohata R., Iwamoto M., Kitawaki T., Kusachi S., Sakaguchi K., Ohe T., Serum interferon-gamma-inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size. Clinical Biochemistry 2008 41 1-2 30 37 2-s2.0-36749009176 10.1016/j.clinbiochem.2007.10. 001 (Pubitemid 350216829)
41. Ørn S., Breland U. M., Mollnes T. E., Manhenke C., Dickstein K., Aukrust P., Ueland T., The chemokine network in relation to infarct size and left ventricular remodeling following acute myocardial infarction. American Journal of Cardiology 2009 104 9 1179 1183 2-s2.0-71749088822 10.1016/j.amjcard.2009.06.028
42. Teraa M., Sprengers R. W., Westerweel P. E., Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. PLoS ONE 2013 8 e55592
43. Romagnani P., Crescioli C., CXCL10: a candidate biomarker in transplantation. Clinica Chimica Acta 2012 413 1364 1373 2-s2.0-84857684486 10.1016/j.cca.2012.02.009
44. Billottet C., Quemener C., Bikfalvi A., CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochimica et Biophysica Acta 2013 1836 287 295
45. Lu B., Humbles A., Bota D., Structure and function of the murine chemokine receptor CXCR3. European Journal of Immunology 1999 29 3804 3812 (Pubitemid 29527830)
46. Lasagni L., Francalanci M., Annunziato F., Lazzeri E., Giannini S., Cosmi L., Sagrinati C., Mazzinghi B., Orlando C., Maggi E., Marra F., Romagnani S., Serio M., Romagnani P., An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. Journal of Experimental Medicine 2003 197 11 1537 1549 2-s2.0-12444260282 10.1084/jem.20021897 (Pubitemid 36682550)
47. Ehlert J. E., Addison C. A., Burdick M. D., Kunkel S. L., Strieter R. M., Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. Journal of Immunology 2004 173 10 6234 6240 2-s2.0-8444241446 (Pubitemid 39487781)
48. Yang J., Richmond A., The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Molecular Therapy 2004 9 6 846 855 2-s2.0-3042855031 10.1016/j.ymthe.2004.01.010 (Pubitemid 38878130)
49. Taub D. D., Lloyd A. R., Conlon K., Ji Ming Wang J. M. W., Ortaldo J. R., Harada A., Matsushima K., Kelvin D. J., Oppenheim J. J., Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. Journal of Experimental Medicine 1993 177 6 1809 1814 2-s2.0-0027315862 (Pubitemid 23146150)
50. Loetscher M., Loetscher P., Brass N., Meese E., Moser B., Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. European Journal of Immunology 1998 28 3696 3705 (Pubitemid 28510780)
51. Brightling C. E., Ammit A. J., Kaur D., Black J. L., Wardlaw A. J., Hughes J. M., Bradding P., The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. American Journal of Respiratory and Critical Care Medicine 2005 171 10 1103 1108 2-s2.0-18644380441 10.1164/rccm.200409-1220OC (Pubitemid 40663721)
52. Saunders R., Sutcliffe A., Kaur D., Siddiqui S., Hollins F., Wardlaw A., Bradding P., Brightling C., Airway smooth muscle chemokine receptor expression and function in asthma. Clinical and Experimental Allergy 2009 39 11 1684 1692 2-s2.0-70350331595 10.1111/j.1365-2222.2009.03310.x
53. Wu Q., Dhir R., Wells A., Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Molecular Cancer 2012 11, article 3 1 17 2-s2.0-84855603328 10.1186/1476-4598-11-3
54. Wallace A. E., Cartwright J. E., Begum R., Trophoblast-induced changes in C-x-C motif chemokine 10 expression contribute to vascular smooth muscle cell dedifferentiation during spiral artery remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology 2013 33 e93 e101
55. Bodnar R. J., Yates C. C., Wells A., IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circulation Research 2006 98 5 617 625 2-s2.0-33645319035 10.1161/01.RES.0000209968.66606.10
56. Bodnar R. J., Yates C. C., Rodgers M. E., Du X., Wells A., IP-10 induces dissociation of newly formed blood vessels. Journal of Cell Science 2009 122 12 2064 2077 2-s2.0-68949181600 10.1242/jcs.048793
57. Yates-Binder C. C., Rodgers M., Jaynes J., An IP-10 (CXCL10)-derived peptide inhibits angiogenesis. PLoS ONE 2012 7 e40812
58. Wentzel J. J., Gijsen F. J. H., Stergiopulos N., Serruys P. W., Slager C. J., Krams R., Shear stress, vascular remodeling and neointimal formation. Journal of Biomechanics 2003 36 5 681 688 2-s2.0-0037402764 10.1016/S0021- 9290(02)00446-3 (Pubitemid 36407620)
59. Hansson G. K., Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 2005 353 4 429 430 2-s2.0-22844433205 10.1056/NEJM200507283530425 (Pubitemid 41132355)
60. Libby P., Inflammation in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 2045 2051
61. Spagnoli L. G., Bonanno E., Sangiorgi G., Mauriello A., Role of inflammation in atherosclerosis. Journal of Nuclear Medicine 2007 48 11 1800 1815 2-s2.0-36048950802 10.2967/jnumed.107.038661 (Pubitemid 350099325)
62. Mach F., Sauty A., Iarossi A. S., Sukhova G. K., Neote K., Libby P., Luster A. D., Differential expression of three t lymphocyte-activating CXC chemokines by human atheroma-associated cells. Journal of Clinical Investigation 1999 104 8 1041 1050 2-s2.0-0032749367 (Pubitemid 29536314)
63. Kawamura A., Miura S.-I., Fujino M., Nishikawa H., Matsuo Y., Tanigawa H., Tomita S., Tsuchiya Y., Matsuo K., Saku K., CXCR3 chemokine receptor-plasma IP10 interaction in patients with coronary artery disease. Circulation Journal 2003 67 10 851 854 2-s2.0-10744229936 10.1253/circj.67.851 (Pubitemid 37229223)
64. Zuojun H., Lingyu H., Wei H., Henghui Y., Chonggang Z., Jingsong W., Mian W., Yong L., Shenming W., Interference of IP-10 expression inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in carotid artery: a new insight in the prevention of restenosis. Cell Biochemistry and Biophysics 2012 62 1 125 135 2-s2.0-84855591684 10.1007/s12013-011-9270-9
65. Johnsen S. H., Forsdahl S. H., Singh K., Jacobsen B. K., Atherosclerosis in abdominal aortic aneurysms: a causal event or a process running in parallel? The tromsø study. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 6 1263 1268 2-s2.0-77952886312 10.1161/ATVBAHA.110.203588
66. Lederle F. A., Johnson G. R., Wilson S. E., Chute E. P., Littooy F. N., Bandyk D., Krupski W. C., Barone G. W., Acher C. W., Ballard D. J., Prevalence and associations of abdominal aortic aneurysm detected through screening. Annals of Internal Medicine 1997 126 6 441 449 2-s2.0-0031055721 (Pubitemid 27114472)
67. Pearce W. H., Koch A. E., Cellular components and features of immune response in abdominal aortic aneurysms. Annals of the New York Academy of Sciences 1996 800 175 185 2-s2.0-0030447378 (Pubitemid 27028954)
68. Sagan A., Mrowiecki W., Mikolajczyk T. P., Local inflammation is associated with aortic thrombus formation in abdominal aortic aneurysms. Relationship to clinical risk factors. Journal of Thrombosis and Haemostasis 2012 108 812 823
69. Koole D., Zandvoort H. J. A., Schoneveld A., Intraluminal abdominal aortic aneurysm thrombus is associated with disruption of wall integrity. Journal of Vascular Surgery 2013 57 77 83
70. Frangogiannis N. G., Entman M. L., Chemokines in myocardial ischemia. Trends in Cardiovascular Medicine 2005 15 5 163 169 2-s2.0-24744439919 10.1016/j.tcm.2005.06.005 (Pubitemid 41297626)
71. Shiraha H., Glading A., Gupta K., Wells A., IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal growth factor receptor-mediated calpain activity. Journal of Cell Biology 1999 146 1 243 253 2-s2.0-0033549526 10.1083/jcb.146.1.243 (Pubitemid 29349978)
72. Schaper W., Collateral circulation. Past and present. Basic Research in Cardiology 2009 104 1 5 21 2-s2.0-57949098602 10.1007/s00395-008-0760-x
73. Carmeliet P., Mechanisms of angiogenesis and arteriogenesis. Nature Medicine 2000 6 4 389 395 2-s2.0-0034076189 10.1038/74651 (Pubitemid 30208155)
74. Scholz D., Ito W., Fleming I., Deindl E., Sauer A., Wiesnet M., Busse R., Schaper J., Schaper W., Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). Virchows Archiv 2000 436 3 257 270 2-s2.0-0034108475 (Pubitemid 30168685)
75. Cai W., Schaper W., Mechanisms of arteriogenesis. Acta Biochimica et Biophysica Sinica 2008 40 8 681 692 2-s2.0-49649096385 10.1111/j.1745-7270.2008. 00436.x
76. Shireman P. K., The chemokine system in arteriogenesis and hind limb ischemia. Journal of Vascular Surgery 2007 45 6 48 56 2-s2.0-34249326588 10.1016/j.jvs.2007.02.030 (Pubitemid 46818865)
77. van Royen N., Hoefer I., Buschmann I., Kostin S., Voskuil M., Bode C., Schaper W., Piek J. J., Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. Cardiovascular Research 2003 57 1 178 185 2-s2.0-12244281846 10.1016/S0008-6363(02)00615-6 (Pubitemid 36009449)
78. Voskuil M., Hoefer I. E., van Royen N., Hua J., de Graaf S., Bode C., Buschmann I. R., Piek J. J., Abnormal monocyte recruitment and collateral artery formation in monocyte chemoattractant protein-1 deficient mice. Vascular Medicine 2004 9 4 287 292 2-s2.0-13444259810 10.1191/1358863x04vm571oa (Pubitemid 40202245)
79. Kraaijeveld A. O., de Jager S. C. A., de Jager W. J., Prakken B. J., McColl S. R., Haspels I., Putter H., van Berkel T. J. C., Nagelkerken L., Jukema J. W., Biessen E. A. L., CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007 116 17 1931 1941 2-s2.0-37349016235 10.1161/CIRCULATIONAHA.107.706986 (Pubitemid 350287089)
80. Davì G., Tuttolomondo A., Santilli F., Basili S., Ferrante E., di Raimondo D., Pinto A., Licata G., CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. Journal of Atherosclerosis and Thrombosis 2009 16 6 707 713 2-s2.0-77950345712
81. Canouï-Poitrine F., Luc G., Mallat Z., Machez E., Bingham A., Ferrieres J., Ruidavets J.-B., Montaye M., Yarnell J., Haas B., Arveiler D., Morange P., Kee F., Evans A., Amouyel P., Ducimetiere P., Empana J.-P., Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study. Neurology 2011 77 12 1165 1173 2-s2.0-80555125083 10.1212/WNL. 0b013e31822dc7c8
82. de Jager S. C. A., Bongaerts B. W. C., Weber M., Chemokines CCL3/MIP1 α CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes. PLoS ONE 2012 7 e45804
83. Aukrust P., Halvorsen B., Yndestad A., Ueland T., Øie E., Otterdal K., Gullestad L., Damås J. K., Chemokines and cardiovascular risk. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 11 1909 1919 2-s2.0-55449102885 10.1161/ATVBAHA.107.161240
84. Aukrust P., Yndestad A., Smith C., Ueland T., Gullestad L., Damås J. K., Chemokines in cardiovascular risk prediction. Thrombosis and Haemostasis 2007 97 5 748 754 2-s2.0-34249008094 10.1160/TH07-01-0029 (Pubitemid 46779960)
85. Harismendy O., Notani D., Song X., Rahim N. G., Tanasa B., Heintzman N., Ren B., Fu X.-D., Topol E. J., Rosenfeld M. G., Frazer K. A., 9p21 DNA variants associated with coronary artery disease impair interferon- γ 3 signalling response. Nature 2011 470 7333 264 268 2-s2.0-79951473520 10.1038/nature09753
86. Erridge C., Gracey J., Braund P. S., Samani N. J., The 9p21 locus does not affect risk of coronary artery disease through induction of type 1 interferons. Journal of the American College of Cardiology 2013 62 1376 1381